Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | GFER | P55789 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913402 | 0.84 | CYP3A4 (0.41) | CYP3A4KEAP1POLBALDH1A1DPP4 | |
| SCHEMBL2334297 | 0.83 | DPP4 (0.41) | KEAP1ALDH1A1DPP4ALOX15TSHR | |
| SCHEMBL21750024 | 0.81 | KEAP1 (0.45) | KEAP1POLBALDH1A1KMT2AKDM4E | |
| SCHEMBL7015064 | 0.79 | DPP4 (0.48) | CYP3A4KEAP1POLBALDH1A1DPP4 | |
| SCHEMBL2203971 | 0.79 | KEAP1 (0.44) | KEAP1POLBALDH1A1KMT2AKDM4E | |
| SCHEMBL1358784 | 0.79 | DPP4 (0.54) | ALDH1A1DPP4ALOX15TSHRKDM4E | |
| SCHEMBL21435217 | 0.78 | ABL1 (0.47) | POLBALDH1A1ALOX15TSHRKMT2A | |
| Potassium SCHEMBL30811378 | 0.78 | DPP4 (0.52) | ALDH1A1DPP4ALOX15TSHRKDM4E | |
| SCHEMBL29181700 | 0.78 | DPP4 (0.52) | ALDH1A1DPP4ALOX15TSHRKDM4E | |
| SCHEMBL3574434 | 0.78 | DPP4 (0.47) | KEAP1POLBALDH1A1DPP4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12447151-B2 | Alkyne derivative, preparation method for same, and uses thereof | HIS PHARMACEUTICAL CO., LTD. (CN) | 2025-10-21 | — | — | US | disclosed |
| EP-4359415-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-115785084-B | Pyrimidine derivatives and their use in medicine | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-114072409-B | Alkyne derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-115785084-A | Pyrimidine derivatives and their use in medicine | 广东东阳光药业有限公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022271684-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271684-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220257602-A1 | ALKYNE DERIVATIVE, PREPARATION METHOD FOR SAME, AND USES THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2022-08-18 | — | — | US | disclosed |
| CN-114685395-A | 2, 3-dihydrobenzo [ d ] isothiazole compound and application thereof | 浙江大学 | 2022-07-01 | — | — | CN | disclosed |
| EP-3998270-A1 | ALKYNE DERIVATIVE, PREPARATION METHOD FOR SAME, AND USES THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| US-10899769-B2 | Imidazopiperazinone inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3619205-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-03-11 | — | — | EP | disclosed |
| US-20190308978-A1 | IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-10 | — | — | US | disclosed |
| WO-2019195846-A1 | IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195846-A1 | IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190308978-A1 | IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-10 | — | — | US | disclosed |
| WO-2018203235-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-11-08 | — | — | WO | disclosed |
| US-20180105527-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-19 | — | — | US | disclosed |
| US-20180105527-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-19 | — | — | US | disclosed |
| WO-2014128612-A1 | QUINAZOLIN-4-ONE DERIVATIVES | NOVARTIS AG (CH) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257602-A1 | ALKYNE DERIVATIVE, PREPARATION METHOD FOR SAME, AND USES THEREOF | PIK3CD, PIK3R5, PIK3CA | CYP3A4 1650/4885KEAP1 3507/4885POLB 2816/4885 |
| US-20180105527-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | WEE2, WEE1, ITK | CYP3A4 922/4885KEAP1 2088/4885POLB 3532/4885 |
| US-10899769-B2 | Imidazopiperazinone inhibitors of transcription activating proteins | EP300, CREBBP, RBBP4 | CYP3A4 4616/4885KEAP1 1097/4885POLB 1093/4885 |
| US-12447151-B2 | Alkyne derivative, preparation method for same, and uses thereof | PIK3CD, PIK3R5, PIK3CA | CYP3A4 1650/4885KEAP1 3507/4885POLB 2816/4885 |
| US-20190308978-A1 | IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP4 | CYP3A4 4616/4885KEAP1 1097/4885POLB 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.